10-Year natural course of early hip osteoarthritis in middle-aged persons with hip pain: a CHECK study.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
04 2021
Historique:
received: 17 07 2020
revised: 14 10 2020
accepted: 06 11 2020
pubmed: 17 1 2021
medline: 28 6 2022
entrez: 16 1 2021
Statut: ppublish

Résumé

To explore the natural course of hip osteoarthritis (OA) in a population of first-time presenters with hip complaints. Data were collected at baseline and after 2, 5, 8 and 10 years on participants from the Cohort Hip and Cohort Knee study with early symptomatic hip OA. Descriptive statistics were used to analyse the natural course of the hip complaints with respect to clinical signs and symptoms, physical functioning and radiographic osteoarthritis (ROA) features. In total, 588 participants were included with hip complaints and 86% completed the 10-year follow-up. The 10-year follow-up showed that 12% (69 participants) underwent hip replacement (HR), an increase of ROA of the hip (Kellgren and Lawrence score≥2) from 19% to 49%, and an increase in clinical hip OA according to the American College of Rheumatology criteria from 27% to 43%. All Western Ontario and McMaster Osteoarthritis Index subscales and physical activity remained on average constant during the 10-year follow-up for those who did not undergo an HR. The use of pain medication increased from 43% at baseline to 50% after 10 years. One out of nine participants with early hip problems received an HR during the 10-year follow-up. Prevalence of clinical hip OA and hip ROA increased steadily during the 10-year follow-up. Overall, we observed more hip OA, but fewer or stable complaints with respect to clinical signs and symptoms, and physical functioning. So it could be cautiously concluded that after 10 years, first-time presenters with hip complaints either received an HR or their symptoms remained stable.

Identifiants

pubmed: 33451999
pii: annrheumdis-2020-218625
doi: 10.1136/annrheumdis-2020-218625
pmc: PMC7958083
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

487-493

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Annemaria C van Berkel (AC)

Department of General Practice, Erasmus MC, University Medical Center, Rotterdam, The Netherlands a.vanberkel@erasmusmc.nl.

Dieuwke Schiphof (D)

Department of General Practice, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Jan H Waarsing (JH)

Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Jos Runhaar (J)

Department of General Practice, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

John M van Ochten (JM)

Department of General Practice, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Patrick J E Bindels (PJE)

Department of General Practice, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Sita M A Bierma-Zeinstra (SMA)

Department of General Practice, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH